Big bet Sanofi doesn't seem to think the lung tests will be a major barrier to sales. In exchange for a 65% stake in Afrezza, Sanofi gave MannKind $150 million upfront and has already paid another $50 million in milestone payments related to completing launch preparations. There's still another $675 million left to earn, and Saonfi agreed to loan MannKind enough money to cover the biotech's portion of the losses from the partnership, up to $175 million.